We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1, 2024.

Furthermore, the duration of acceptance has been changed, since the 3-year limit has been withdrawn.

Please find attached Bayer’s information letter: BE.XAR.VAE_Remboursement CADPAD_FR